Skip to main content

CASE REPORT article

Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1447140
This article is part of the Research Topic Innovative Approaches to Overcome Resistance and Toxicities of Anti-Cancer Drugs View all 20 articles

The Addition of PD-1 Inhibitor Overcame Trastuzumab Resistance in Patients with HER2 Positive, PD-L1 Negative Metastatic Gastric Cancer: Case Report and Review of Literature

Provisionally accepted
Zhenpeng Wen Zhenpeng Wen 1Daoli Ye Daoli Ye 2,3Qiancheng Hu Qiancheng Hu 1,2HongFeng Gou HongFeng Gou 1,2*
  • 1 Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
  • 2 Gastric Cancer Center, West China Hospital, Sichuan University, Chengdu, China
  • 3 West China School of Nursing, Sichuan University, Chengdu, Sichuan Province, China

The final, formatted version of the article will be published soon.

    Gastric cancer (GC) is a malignancy with poor prognosis and high heterogeneity. For HER2-positive, PD-L1 negative metastatic GC patients, chemotherapy plus trastuzumab is the first-line therapy.However, those patients soon acquired resistance to treatment, especially to trastuzumab during the treatment. How to improve the therapeutic resistance of HER2-positive, PD-L1 negative metastatic GC is still a dilemma. We present the case of a metastatic GC patient with HER2 positive and PD-L1 negative expression who suffered progression after a short remission with trastuzumab plus chemotherapy. The patient exhibited a strong heterogeneity in the primary and metastatic lesions.His resistance to trastuzumab was overcome after the addition of a PD-1 inhibitor, then he received a durable response more than eight months. In HER2 positive, PD-L1 negative metastatic GC, the addition of PD-1 inhibitor after first-line chemotherapy and trastuzumab treatment resistance may be an option.

    Keywords: PD-1 inhibitor, Trastuzumab resistance, HER2, PD-L1, gastric cancer

    Received: 11 Jun 2024; Accepted: 04 Oct 2024.

    Copyright: © 2024 Wen, Ye, Hu and Gou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: HongFeng Gou, Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.